NBIX Neurocrine Biosciences Inc

USD 110.22 -0.71 (-0.64%)
At close: 04:00PM EST
Icon

Neurocrine Biosciences Inc Stock Analysis and Price Target COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

stockTargetAdvisor

Buy

Average User
Rating
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis

USD 110.22

-0.71 (-0.64)%

USD 10.41B

0.82M

USD 119.77(+8.67%)

USD 100.00 (-9.27%)

Icon

NBIX

Neurocrine Biosciences Inc (USD)
COMMON STOCK | NSD
USD 110.22
-0.71 (-0.64%)
At close: 04:00PM EST
stockTargetAdvisor

Buy

Average User
Rating
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis

USD 10.41B

USD 100.00 (-9.27%)

USD 110.22

Neurocrine Biosciences Inc Stock Forecast

USD 119.77
(+8.67%)

Based on the Neurocrine Biosciences Inc stock forecasts from 15 analysts, the average analyst target price for Neurocrine Biosciences Inc is USD 119.77 over the next 12 months. Neurocrine Biosciences Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Neurocrine Biosciences Inc is Bullish , which is based on 11 positive signals and 4 negative signals. At the last closing, Neurocrine Biosciences Inc’s stock price was USD 110.22. Neurocrine Biosciences Inc’s stock price has changed by +1.31% over the past week, -7.72% over the past month and +39.13% over the last year.

No recent analyst target price found for Neurocrine Biosciences Inc
No recent average analyst rating found for Neurocrine Biosciences Inc

Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical ...Read More

https://www.neurocrine.com

12780 El Camino Real, San Diego, CA, United States, 92130

1,150

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

  • 0.52

  • USD 129.29

  • 3.35

  • USD 75.25

  • 2,594,066

  • USD 104.62

  • 2,251,549

  • USD 117.07

  • 1.00%

  • 3.10%

  • 96.92%

  • N/A

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Security Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Neurocrine Biosciences Inc (Sector: Drug Manufacturers-Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD
PPD Inc 0.00 (0.00%) USD16.61B 47.04 21.58
VTRS
Viatris Inc +0.10 (+0.82%) USD14.42B 18.02 6.97
MYL
Mylan N.V 0.00 (0.00%) USD8.59B 30.73 11.86
APHA
Tilray, Inc 0.00 (0.00%) USD6.86B 60.60 454.68
MNTA
Momenta Pharmaceuticals, Inc 0.00 (0.00%) USD6.24B N/A N/A
ALKS
Alkermes Plc +0.05 (+0.17%) USD4.73B N/A -72.85
ITCI
Intracellular Th -0.10 (-0.21%) USD4.45B N/A -14.58
LNTH
Lantheus Holdings Inc +1.14 (+1.98%) USD3.86B 36.91 16.96
EVO
Evotec SE ADR +0.10 (+1.03%) USD3.66B 508.00 -19.09
HCM
HUTCHMED DRC +0.73 (+4.05%) USD3.64B 17.69 -6.38

ETFs Containing NBIX

Symbol Name Weight Mer Price(Change) Market Cap
PBE
Invesco Dynamic Biotechno.. 4.30 % 0.57 % +0.39 (+0.58%) USD0.26B
IVOG
Vanguard S&P Mid-Cap 400 .. 1.10 % 0.08 % +2.57 (+1.42%) USD0.75B
VBK
Vanguard Small-Cap Growth.. 0.63 % 0.07 % +4.94 (+2.21%) USD13.26B
MDY
SPDR® S&P MIDCAP 400 ETF.. 0.56 % 0.22 % +7.75 (+1.60%) USD19.78B
SPY4:LSE
SSgA SPDR ETFs Europe I P.. 0.56 % 0.30 % +1.05 (+1.33%) USD1.35B
IVOO
Vanguard S&P Mid-Cap 400 .. 0.55 % 0.08 % +2.72 (+1.52%) USD1.54B

Frequently Asked Questions About NBIX Stock

Based on ratings from 15 analysts Neurocrine Biosciences Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 5 buy, sell and 9 hold ratings.

Unfortunately we do not have enough data on NBIX's stock to indicate if its a good dividend stock.

Based on targets from 15 analysts, the average taret price for NBIX is USD 119.77 over the next 12 months. The maximum analyst target price is USD 150 while the minimum anlayst target price is USD 78.

NBIX stock's Price/Earning ratio is 180.48. Our analysis grades NBIX stock's Price / Earning ratio at F. This means that NBIX stock's Price/Earning ratio is above 96% of the stocks in the Drug Manufacturers-Specialty & Generic sector in the NSD exchange. Based on this NBIX may be a overvalued for its sector.

The last closing price of NBIX's stock was USD 110.22.

The most recent market capitalization for NBIX is USD 10.41B.

Based on targets from 15 analysts, the average taret price for NBIX is projected at USD 119.77 over the next 12 months. This means that NBIX's stock price may go up by +8.67% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...